{
    "nctId": "NCT02025712",
    "briefTitle": "Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer",
    "officialTitle": "A Phase II Open-label Pilot Study Evaluating the Maintenance Therapy With Exemestane Plus Everolimus After Induction Chemotherapy in Patients With Hormone-receptor Positive Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Hormone Receptor Positive Malignant Neoplasm of Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women as defined in the protocol page 9;\n* Histologically and/or cytologically confirmed invasive breast cancer with stage IV disease according to AJCC;\n* Confirmed ER/PR-positive, and HER-2 negative tumor;\n* Disease progression on or following prior endocrine therapy with tamoxifen or non-steroidal aromatase inhibitor, as defined in protocol, prior to standard of care (SOC) induction chemotherapy\n* Patient with documented evidence of visceral disease (including but not limited to hepatic involvement and pulmonary lymphangitic spread of tumor) with sign(s) and/or symptom(s) prior to SOC induction chemotherapy should achieve disease stabilization after the SOC induction chemotherapy, confirmed upon 2 consecutive routine tumor assessments;\n* ECOG performance status \u2264 2 or Karnofsky performance status \u2265 50% prior to the start of study treatment;\n* Adequate organ function prior to the start of study treatment as defined in the protocol;\n* Able to swallow and retain oral medication;\n* Able to give written informed consent;\n\nExclusion Criteria:\n\n* Male patient;\n* Metastatic disease limited to the bone or soft tissues only and with no history of other visceral metastases;\n* History of brain or other CNS metastases;\n* Previous treatment with exemestane, unless exemestane was administered in the adjuvant setting and stopped \\>1 year before metastatic relapse;\n* Untreated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC - or - treated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC without clinical benefit;\n* History of neurological or psychiatric disorders;\n* Any serious cardiovascular diseases in the previous 6 months;\n* Impairment of gastrointestinal function or gastrointestinal disease;\n* Patients with uncontrolled infection;\n* Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin defined as 1 mg a day);\n* Chronic treatment with systemic steroids or another immunosuppressive agent;\n* Patients with a pre-existing peripheral neuropathy \\> grade 1;\n* Patients who are hepatitis B and/or hepatitis C carriers;\n* Known human immunodeficiency virus infection;\n* Prior exposure to mTOR inhibitors;\n* Hypersensitivity to rapamycin or other similar compounds;\n* Patients taking medications known to be inhibitors or inducers of CYP3A4 and/or PgP will not be included in this study;\n* Prior treatment with any investigational agent within the preceding 4 weeks;\n* Other conditions in the judgment of the investigator, would make the patient inappropriate for entry into this study.\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}